HighTower Advisors
CRSP icon

HighTower Advisors’s CRISPR Therapeutics CRSP Stock Holding History

HighTower Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$1K – 3455
2021
Q4 		$1K Buy
+2
New +$175 ﹤0.01% 3255

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighTower Advisors's CRSP Position: Q2 2026 in Review

HighTower Advisors reduced its CRISPR Therapeutics (CRSP) stake by 1.4% in Q2 2026, selling an estimated $18.6K and leaving 24,652 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2053.

HighTower Advisors first reported a position in CRSP in Q2 2018 and has held it in 33 quarters since. The position peaked at $6.49M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • HighTower Advisors held 24,652 shares of CRISPR Therapeutics worth $1.34M as of Q2 2026.
  • HighTower Advisors sold 352 CRISPR Therapeutics shares in Q2 2026, an estimated $18.6K.
  • CRISPR Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2053 holding.
  • HighTower Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 33 quarters since.
  • HighTower Advisors's CRISPR Therapeutics position peaked at $6.49M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.